IMNM Q2 2022 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$9M

Net Income

-$9M

EPS (Diluted)

$-0.74

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$39M

Total Liabilities

$9M

Stockholders' Equity

$30M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$9M	-$6M	-55.5%
Net Income	-$9M	-$5M	-70.3%